Brian Park, PharmD

Drug Information Specialist https://www.pulmonologyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Restrictive Lung Disease

Nintedanib Granted Breakthrough Therapy for Progressive Fibrosing Interstitial Lung Disease

Brian Park, PharmD

October 15, 2019

The FDA has granted Breakthrough Therapy designation to nintedanib for the treatment of chronic fibrosing ILDs with a progressive phenotype.

Smoking

FDA: Stop Using Vaping Products Containing THC

Brian Park, PharmD

October 9, 2019

An updated alert from the Food and Drug Administration is warning consumers to stop using e-cigarettes or vapes.

Allergies

FDA to Review Epicutaneous Immunotherapy for Peanut Allergy

Brian Park, PharmD

October 9, 2019

The FDA has accepted for review the BLA for Viaskin Peanut (DBV Technologies) for the treatment of peanut-allergic children aged 4 to 11 years.

Pneumonia

Cefiderocol Compared With Meropenem for Nosocomial Pneumonia Treatment

Brian Park, PharmD

October 7, 2019

Shionogi has announced positive results from the phase 3 APEKS-NP trial of cefiderocol (S-649266) for the treatment of nosocomial pneumonia.

Maternal Tdap vaccination lowers risk of pertussis in newborns

Lung Cancer

BCG Vaccination and Cancer Risk: What’s the Link?

Brian Park, PharmD

September 30, 2019

BCG vaccination in childhood was associated with a reduced risk of lung cancer development in American Indian and Alaska Native populations.

Uncategorized

FDA Panel Votes on OTC Nicotine Mouth Spray for Smoking Cessation

Brian Park, PharmD

September 26, 2019

The NDAC of the FDA has recommended approval of the NDA from GSK for an OTC nicotine mouth spray to aid in smoking cessation.

Lung Cancer

First-Line Pembrolizumab Effective in Advanced NSCLC, According to 3-Year Follow-Up Data

Brian Park, PharmD

September 23, 2019

First-line pembrolizumab monotherapy provides durable long-term overall survival benefit compared with chemotherapy.

Lung Cancer

Nivolumab vs Docetaxel: 5-Year Outcomes in Patients With Advanced NSCLC

Brian Park, PharmD

September 20, 2019

Treatment with nivolumab was associated with a 5-fold increase in overall survival compared with chemotherapy, in patients with previously treated non-small cell lung cancer.

Prevention

FDA Warns of Possible Interstitial Lung Disease, Pneumonitis With Certain Breast Cancer Drugs

Brian Park, PharmD

September 19, 2019

Healthcare professionals are being advised to monitor patients regularly for pulmonary symptoms indicative of ILD and/or pneumonitis, including hypoxia, cough, dyspnea, and interstitial infiltrates on radiologic exams.

Pulmonary Hypertension

Sotatercept Receives Orphan Drug Status for Pulmonary Arterial Hypertension

Brian Park, PharmD

September 13, 2019

The FDA has granted Orphan Drug designation to sotatercept for the treatment of patients with pulmonary arterial hypertension.

Next post in Pulmonary Hypertension